ETH Zurich

ETH Zurich Identifies Novel Alzheimer's Target GRK2, Compound 10 Shows Preclinical Efficacy

ETH Zurich has unveiled Compound 10, a preclinical asset targeting GRK2 protein aggregates, a newly identified Alzheimer's trigger. In mouse models, Compound 10 reduced nerve cell loss and amyloid beta, offering a novel mechanism distinct from existing therapies. This breakthrough presents a significant partnership opportunity for pharmaceutical firms seeking to acquire a promising early-stage asset in neurology.